Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

MYC overexpression (18)

BCL2 overexpression (17)

MYC expression (9)

BCL2 expression (9)

BCL2 expression + MYC expression (8)

MYC overexpression + BCL2 overexpression (7)

BCL2 positive (7)

MYC positive (3)

MYC expression + BCL2 expression (2)

MYC underexpression (2)

miR-17-HG overexpression + MYC positive (2)

BCL2 overexpression + MCL1 overexpression (2)

BCL2 underexpression (2)

BCL2 overexpression + MYC overexpression (1)

BTK expression + BCL2 expression + MYC expression (1)

BTK expression + MYC expression (1)

CHEK1 overexpression + MYC overexpression (1)

MYC expression + BCL2 expression + BCL6 expression (1)

MYC expression + MCL1 expression (1)

MYC negative (1)

MYC positive + BCL2 positive (1)

MYC positive + BCL2 positive + BCL6 positive (1)

MYC expression + PAICS expression (1)

OTUD6B expression + MYC expression (1)

miR-17-HG expression + MYC positive (1)

BCL2 overexpression + CCND1 overexpression (1)

BCL2 overexpression + MCL1 expression (1)

BCL2 overexpression + MCL1 underxpression + BCL2L1 underexpression (1)

BCL2 positive + LGALS3 expression (1)

BTK expression + BCL2 expression (1)

CASP3 overexpression + BCL2 negative (1)

CASP3 underexpression + BCL2 positive (1)

CD20 expression + PAX5 expression + BCL2 expression (1)

CD22 underexpression + BCL2 overexpression (1)

BCL6 overexpression (1)

BCL6 positive (1)

BCL2 positive + IGH positive (0)

MYC overexpression (18)

BCL2 overexpression (17)

MYC expression (9)

BCL2 expression (9)

BCL2 expression + MYC expression (8)

MYC overexpression + BCL2 overexpression (7)

BCL2 positive (7)

MYC positive (3)

MYC expression + BCL2 expression (2)

MYC underexpression (2)

miR-17-HG overexpression + MYC positive (2)

BCL2 overexpression + MCL1 overexpression (2)

BCL2 underexpression (2)

BCL2 overexpression + MYC overexpression (1)

BTK expression + BCL2 expression + MYC expression (1)

BTK expression + MYC expression (1)

CHEK1 overexpression + MYC overexpression (1)

MYC expression + BCL2 expression + BCL6 expression (1)

MYC expression + MCL1 expression (1)

MYC negative (1)

MYC positive + BCL2 positive (1)

MYC positive + BCL2 positive + BCL6 positive (1)

MYC expression + PAICS expression (1)

OTUD6B expression + MYC expression (1)

miR-17-HG expression + MYC positive (1)

BCL2 overexpression + CCND1 overexpression (1)

BCL2 overexpression + MCL1 expression (1)

BCL2 overexpression + MCL1 underxpression + BCL2L1 underexpression (1)

BCL2 positive + LGALS3 expression (1)

BTK expression + BCL2 expression (1)

CASP3 overexpression + BCL2 negative (1)

CASP3 underexpression + BCL2 positive (1)

CD20 expression + PAX5 expression + BCL2 expression (1)

CD22 underexpression + BCL2 overexpression (1)

BCL6 overexpression (1)

BCL6 positive (1)

BCL2 positive + IGH positive (0)

›

MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Lymphoma	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	loncastuximab tesirine-lpyl Sensitive: C3 – Early Trials loncastuximab tesirine-lpyl Sensitive : C3	loncastuximab tesirine-lpyl Sensitive: C3 – Early Trials loncastuximab tesirine-lpyl Sensitive : C3
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3	axicabtagene ciloleucel Sensitive: C3 – Early Trials axicabtagene ciloleucel Sensitive : C3
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	acalabrutinib Sensitive: C4 – Case Studies acalabrutinib Sensitive : C4	acalabrutinib Sensitive: C4 – Case Studies acalabrutinib Sensitive : C4
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Lymphoma	SGN-CD19B Sensitive: D – Preclinical SGN-CD19B Sensitive : D	SGN-CD19B Sensitive: D – Preclinical SGN-CD19B Sensitive : D